Endo International said Sept. 30 the firm reached master settlement agreements with several law firms representing leading plantiffs to resolve claims over vaginal mesh products sold by Endo’s American Medical Systems subsidiary.

The agreements, not an admission of liability or fault, were reached as a  compromise and settlement and should substantially resolve all of the claims, Endo said.

Rajiv De Silva, president and CEO of Endo, said he was pleased with the settlements, which will allow the company to continue to invest in its growth.

Endo said it had previously established a pre-tax product liability reserve of approximately $1.2 billion. As a result of the agreements, the company expects to increase its pre-tax product liability accrual for all future claims to approximately $1.6 billion.  AMS expects to fund the payments under all settlements through 2017.

To date, Endo has paid approximately $200 million into qualified settlement funds.

Endo also said its top priority is the safety and efficacy of its subsidiaries’ products and supporting the patients and physicians who use them.  The company said it will continue to support the FDA’s recommendations that physicians be well trained and patients fully understand the risks associated with the use of mesh products.

Endo said AMS, headquartered in Minnteonka, Mn., will continue developing its women’s health business and devices products so women have appropriate access to innovative, safe and effective therapies.  AMS will also continue to invest in educational activities as part of an overall effort to continue to encourage patients and physicians to discuss the risks and benefits of AMS’s surgical mesh.